Hot Performing Stocks To Invest In Right Now

March 20, 2017: Markets opened slightly lower Monday and traded close to the break-even line all day. Leading indicators and consumer sentiment readings were both strong. Only the materials sector traded high late in the afternoon while energy and utilities were the laggards. The blue chips were performing best. WTI crude oil for April delivery settled at $48.22 a barrel, down 1.2% on the day. April gold added 0.3% on the day to settle at $1,234.00. Equities were headed for a mixed close shortly before the bell as the DJIA traded up 0.03% for the day, the S&P 500 traded down 0.14%, and the Nasdaq Composite traded up 0.02%.

Stocks traded very near the break-even line just minutes before the closing bell. The closing tally could finish with either a small gain or a small loss for any or all of the indexes.

The DJIA stock posting the largest daily percentage gain ahead of the close Monday was Caterpillar Inc. (NYSE: CAT) which traded up 2.66% at $95.38. The stock’s 52-week range is $69.04 to $99.46. Volume was roughly 15% below the daily average of around 5 million shares. The company reported a 1% decline in February retail sales this morning, the best year-over-year mark in more than 4 years.

Hot Performing Stocks To Invest In Right Now: Daktronics, Inc.(DAKT)

Advisors’ Opinion:

  • [By Monica Gerson]

    Daktronics, Inc. (NASDAQ: DAKT) is estimated to report its quarterly earnings at $0.08 per share on revenue of $156.17 million. Daktronics shares slipped 0.13 percent to close at $7.97 on Tuesday.

  • [By Monica Gerson]

    Daktronics, Inc. (NASDAQ: DAKT) is projected to report its quarterly earnings at $0.08 per share on revenue of $156.17 million.

    Guidewire Software Inc (NYSE: GWRE) is estimated to post its quarterly earnings at $0.06 per share on revenue of $92.43 million.

Hot Performing Stocks To Invest In Right Now: Deltic Timber Corporation(DEL)

Advisors’ Opinion:

  • [By Lisa Levin] Gainers
    Aimmune Therapeutics Inc (NASDAQ: AIMT) shares jumped 35 percent to $34.64 in response to failed DBVT peanut allergy trial.
    Exactech, Inc. (NASDAQ: EXAC) shares surged 30.9 percent to $41.88 after the company agreed to be acquired by TPG Capital for $42 per share in cash.
    Dextera Surgical Inc (NASDAQ: DXTR) shares climbed 27.6 percent to $0.238 after surging 40.48 percent on Friday.
    Petmed Express Inc (NASDAQ: PETS) jumped 21.8 percent to $44.73 as the company reported better-than-expected Q2 results.
    SenesTech Inc (NASDAQ: SNES) shares surged 21.7 percent to $1.95 after the company disclosed that Univar will be marketing and selling ContraPest.
    Yulong Eco-Materials Ltd (NASDAQ: YECO) shares gained 18.3 percent to $0.560.
    One Horizon Group Inc (NASDAQ: OHGI) shares rose 18 percent to $1.18.
    Atossa Genetics Inc (NASDAQ: ATOS) shares climbed 18 percent to $0.566. Atossa Genetics is schedule to host a conference call to announce preliminary results from Phase 1 study of oral Endoxifen on October 25, 2017.
    ReneSola Ltd. (ADR) (NYSE: SOL) shares rose 15.3 percent to $2.72
    Renren Inc (NYSE: RENN) shares gained 11.9 percent to $10.71 after gaining 2.68 percent on Friday.
    Kalvista Pharmaceuticals Inc (NASDAQ: KALV) shares rose 11.8 percent to $12.59. KalVista Pharma 13D filing from Longwood Fund showed registration for an 8.7 percent stake.
    Xunlei Ltd (NASDAQ: XNET) shares gained 9.4 percent to $7.20 after surging 25.33 percent on Friday.
    VF Corp (NYSE: VFC) shares surged 7.1 percent to $71.09 after the company reported upbeat earnings for its third quarter and raised its FY2017 guidance.
    CAI International Inc (NYSE: CAI) rose 6.6 percent to $39.70. Cowen & Co. upgraded CAI from Market Perform to Outperform.
    Agenus Inc (NASDAQ: AGEN) shares gained 5.7 percent to $4.58 as the company disclosed that GSK's shingle vaccine received FDA approval.
    Deltic Timber Corp (NYSE: DEL) shares climbed 5.6 percent to $94.11

Hot Performing Stocks To Invest In Right Now: Cubic Corporation(CUB)

Advisors’ Opinion:

  • [By WWW.GURUFOCUS.COM]

    In actuality, we think the reverse is true for several reasons. We believe that there is a higher level of investor neglect in the small cap space, and neglect, in an investment sense, creates valuation discounts from fair value. Small cap names are less well-known and understood. For example, most of you have never heard of Cubic Corporation (NYSE:CUB), but you have likely used the public transportation systems in New York, London, Sydney, etc. that rely on Cubic for fare collection services. Likewise, Multi-Color is a confusing name for the second largest label maker in the world. To understand these businesses, investors need to dig a little deeper with active fundamental research – a Third Avenue strength.

  • [By Lisa Levin]

    Cubic Corporation (NYSE: CUB) shares were also up, gaining 15 percent to $61.45. Cubic reported Q4 net income of $13.2 million, after posting a loss in the year-ago period. Cubic also disclosed that it has been selected for contract from Boston MBTA to deliver next-generation fare payment system.

  • [By Jim Robertson]

    On Friday, small cap Cubic Corporation (NYSE: CUB) had closed up 10.26% with shares rising again in early Monday trading. Cubic Corporation designs, integrates and operates systems, products and services focused in the transportation, defense training and secure communications markets. As the parent company of two major business units,the Companysmission is to increase situational awareness and understanding for customers worldwide. Cubic Transportation Systems is a leading integrator of payment and information technology and services to create intelligent travel solutions for public transit authorities and operators whileCubic Global Defense is a leading provider of realistic combat training systems, secure communications and networking and highly specialized support services for military and security forces of the U.S. and allied nations.

Hot Performing Stocks To Invest In Right Now: NovoCure Limited(NVCR)

Advisors’ Opinion:

  • [By Lisa Levin]

    Novocure Ltd (NASDAQ: NVCR) shares shot up 22 percent to $7.27 after the company posted a narrower-than-expected Q3 loss.

    Shares of TriNet Group Inc (NYSE: TNET) got a boost, shooting up 15 percent to $20.43. TriNet reported Q3 earnings of $0.29 per share on revenue of $770.5 million.

  • [By Chris Lange]

    NocoCure Ltd. (NASDAQ: NVCR) is scheduled to release its fourth-quarter earnings report on February 22 as well. The consensus estimates call for a net loss of $0.11 per share and $53.52 million in revenue. The same period of last year had a net loss of $0.26 per share and $30.24 million in revenue. Shares of Novocure most recently closed at $21.50, with a consensus price target of $27.00 and a 52-week range of $6.75 to $24.15.

Hot Performing Stocks To Invest In Right Now: Biotricity (BTCY)

Advisors’ Opinion:

  • [By James E. Brumley]

    When an investor thinks of stocks in the cardio-monitoring arena, names like General Electric Company (NYSE:GE) and Medtronic PLC (NYSE:MDT) tend to surface first. And well they should. Medtronic is the largest name dedicated solely to equipment that tells doctors and nurses how well a patient’s heart is functioning, while GE Healthcare smartly leverages the name of its parent company’s recognizable name to win market share in the medical equipment space.

    General Electric and Medtronic aren’t the only names in town, however, and certainly not the top prospects for an investor seeking out a fresh, undiscovered growth opportunity. That honor arguably belongs to an up-and-coming small cap outfit called Biotricity Inc. (OTCMKTS:BTCY), which is nearing its first-ever revenue.

    Don’t look for a Biotricity product quite yet, as they’re not on the market. Consumers as well as investors will want to keep their eyes and ears open for two of them soon though, however, with one of those devices being a high-precision, FDA-approved instrument for use by healthcare workers in a clinical setting. The other device is a consumer-oriented version of the same technology, giving BTCY access to not just one but two crucial markets. Even more recently Biotricity reported it was opening up its development pipeline to the fetal monitoring and sleep apnea markets. Heart-monitoring is the near-term venture, though.

    The two products are called biotricity and biolife (neither moniker is supposed to be capitalized). The latter is a wireless, remote consumer-oriented heart rate and activity monitoring device, and the former is a clinical-grade monitoring device… also wireless and remotely operated/monitored.

    Bioflux is only available by prescription. The bioflux hardware includes an ECG (heart-rhythm) monitoring device, software, and if desired, service from a monitoring lab that performs remote diagnostic monitoring for up to 30 consecutive days at a time. It

  • [By James E. Brumley]

    Biotricity Inc (OTCMKTS:BTCY), a developer of remote health-monitoring devices, reminded us not so gently today that while it’s waiting on the last of the necessary approvals from the FDA for its hardware, it’s still moving the ball downfield (so to speak). That is to say, it’s already lined up a manufacturer for its so-called Bioflux cardiac monitor for when the last green light is given, and it’s a good one…. Providence Enterprise . That’s the same company that makes some of the equipment and goods within your sight right now.

    Biotricity is the name behind two pieces of technology, both of which are nearing the end of their development. One is the aforementioned Bioflux, and the other is called biolife…. the latter for use by individuals outside of a clinical setting. Neither is on the market yet, but both are projected to be on the market this year. In fact, the company demonstrated its IoT-connected bioflux at this year’s Mobile World Congress (MWC) 2017 in Barcelona, Spain a couple of weeks ago. The crowd liked what it saw.

    The marketable version of the device isn’t available yet; it’s still going through the approval process. The company recently filed a 510k request with the FDA for its bioflux technology (the 510k path is for medical devices rather than drugs, and as such doesn’t require a lot of regulatory deliberation), and has heard back from the FDA about a key part of the device already – it got the green light. Another arm of the FDA must look at other aspects of the device, and that portion of the review takes longer.

    Still, the company is rightfully optimistic, so much so that it’s already lined up a company to manufacture the Bioflux device once the final approval and final specs are in. That company is Providence Enterprise, which has a long history in making drug delivery and diagnostic equipment, as well as plenty of experience making electronics. The Bioflux will be a blend of both capabilities.

    It’s in

  • [By James E. Brumley]

    When an investor thinks of stocks in the cardio-monitoring arena, names like General Electric Company (NYSE:GE) and Medtronic PLC (NYSE:MDT) tend to surface first. And well they should. Medtronic is the largest name dedicated solely to equipment that tells doctors and nurses how well a patient’s heart is functioning, while GE Healthcare smartly leverages the name of its parent company’s recognizable name to win market share in the medical equipment space.

    General Electric and Medtronic aren’t the only names in town, however, and certainly not the top prospects for an investor seeking out a fresh, undiscovered growth opportunity. That honor arguably belongs to an up-and-coming small cap outfit called Biotricity Inc. (OTCMKTS:BTCY), which is nearing its first-ever revenue.

    Don’t look for a Biotricity product quite yet, as they’re not on the market. Consumers as well as investors will want to keep their eyes and ears open for two of them soon though, however, with one of those devices being a high-precision, FDA-approved instrument for use by healthcare workers in a clinical setting. The other device is a consumer-oriented version of the same technology, giving BTCY access to not just one but two crucial markets. Even more recently Biotricity reported it was opening up its development pipeline to the fetal monitoring and sleep apnea markets. Heart-monitoring is the near-term venture, though.

    The two products are called biotricity and biolife (neither moniker is supposed to be capitalized). The latter is a wireless, remote consumer-oriented heart rate and activity monitoring device, and the former is a clinical-grade monitoring device… also wireless and remotely operated/monitored.

    Bioflux is only available by prescription. The bioflux hardware includes an ECG (heart-rhythm) monitoring device, software, and if desired, service from a monitoring lab that performs remote diagnostic monitoring for up to 30 consecutive days at a time. It

  • [By Robert J. Smith]

    Biotricity (OTCBB: BTCY) is a comer in the rapidly growing medical device market and is a small cap to take notice of. Driving this lucrative market are; IoT-driven device connectivity, governmental pressure to cut healthcare costs, escalating hospital costs, a need to reduce hospital readmission rates, an aging population, and a high rate of people with chronic disease. The largest factor driving this market is the rapidly growing rate of those afflicted with chronic disease.

  • [By Bryan Murphy]

    As much progress as the remote medical monitoring device market has made in recent years, we’ve still only scratched the surface. The surface has been scratched though. The Dexcom G5 mobile glucose monitor from DexCom, Inc. (NASDAQ:DXCM) is one impressive example. Arguably the first and best entry in the race, DexCom has sent a clear message that consumers and caregivers are ready for a functional device that takes care of itself.

    At the other end of the spectrum is a recent round of products that are less clinical in nature, and more broad-usage friendly. Devices like the Apple Inc. (NASDAQ:AAPL) watch and the Fitbit Inc (NYSE:FIT) line of products are both capable of monitoring heart rates and activity. On the other, neither does it all that well… not like one would expect in a clinical setting. Fitbit has run into a headwind of legal and reputational trouble since it’s been verified that its trackers aren’t all that accurate; Apple avoided such trouble largely because few consumers ever viewed its watches as medical-grade hardware.

    The gap between the Dexcom G5 and the Fitbit fitness trackers, however, is where real opportunity lies. See, the entries to date have proven there is a market for mobile medical devices , but have also proven they have to work as well as the equipment one might expect to find in a doctor’s office or in a hospital.

    It’s this subtle nuance that puts a young company called Biotricity Inc. (OTCMKTS:BTCY) in the spotlight, as it has melded mobile monitoring and quality monitoring, and is now in the midst of making sure they’re marketable… not just to consumers, but to insurance companies (which tend to pay a lot more than the average consumer does). Fitbit missed the mark on both fronts.

    Biotricity is working two different but similar pieces of technology. One is called bioflux, for use by caregivers in a clinical setting, and the other is biolife individuals outside of a clinical setting. Neither is o

Hot Performing Stocks To Invest In Right Now: International Paper Company(IP)

Advisors’ Opinion:

  • [By ]

    In the Lightning Round, Cramer was bullish on T-Mobile US (TMUS) , Lennar (LEN) , Toll Brothers (TOL) , Tyson Foods (TSN) , JB Hunt Transport Services (JBHT) and International Paper (IP) .

  • [By WWW.KIPLINGER.COM]

    International Paper Co. (IP) is the largest containerboard maker in the world. And lest you think theres no growth in this old-line industry, IP supplies 50% of Amazon.com, Inc.s (AMZN) need for cardboard boxes.

  • [By ]

    International Paper (IP) : “The stock is down big. I say at these prices it’s a good buy.”

    Alaska Air Group (ALK) : “It used to be the best before the acquisition and now it’s not great and I can’t recommend it anymore.”

Leave a Reply

Your email address will not be published. Required fields are marked *